RTI Biologics Announces 2009 Second Quarter Results

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Biologics Inc. (RTI) (Nasdaq:RTIXNews), a leading processor of orthopedic and other biologic implants, reported operating results for the second quarter ended June 30, 2009 as follows:

Quarterly Highlights:
> Record quarterly revenues of $41.1 million
> Net income of $1 million, or $0.02 per fully diluted share
> Launched five new spine implants with four distributors, including initial implants launched with our newest distributor, Aesculap
> Launched initial dermis implant with ENTrigue for use in the otolaryngology market
> Record quarterly revenue in sports medicine
> Increased number of direct biologic representatives by 6 to a total of 35
> Record revenue of $3.0 million in domestic hernia repair, an increase of more than 140 percent over the previous year’s period

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button